CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 503 enrolled
Drug / intervention
A-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03687372
NCT03687372Phase 3Completed

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

Aclaris Therapeutics, Inc.·interventional·Posted Sep 27, 2018·Updated Oct 5, 2020

In Brief

A Phase 3 clinical trial evaluating A-101 and vehicle for Common Wart. Completed, enrolled 503 participants across 24 sites.

Detailed Summary

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 27, 2018
Enrollment StartSep 17, 2018
Primary CompletionJun 20, 2019
Study CompletionSep 6, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago

Interventions

A-101drug

hydrogen peroxide topical solution 45%

vehicleother

vehicle as a topical solution